Drug prior authorization just became federal ground zero for AI accountability.
On April 10, 2026, CMS published CMS-0062-P — a proposed rule extending prior authorization interoperability requirements to prescription drugs. The Federal Register entry appeared April 14. The comment period runs through June 15, 2026. If this rule finalizes as written, pharmacy operations face hard infrastructure deadlines, tighter payer turnaround windows, and new AI transparency mandates targeting the denial engines that have been running unchecked for years.
This is not incremental. The 2024 Interoperability and Prior Authorization Final Rule (CMS-0057-F) covered non-drug items and services. CMS is now bringing prescription drugs under the same accountability framework. For pharmacy directors, telepharmacy operators, and health system clinical pharmacists, the window to comment — and prepare — is open now.
Clinical Context: Prior Authorization Was Already Broken Before AI
The 2024 AMA prior authorization physician survey found the average physician completes 39 prior authorization requests per week, consuming 13 hours of physician and staff time. Ninety percent of physicians report that PA delays care. Eighty-two percent say patients sometimes abandon treatment entirely because of authorization delays.
Then payers started deploying AI. The result wasn’t faster approvals.
Sixty-one percent of physicians now believe health plan AI is increasing PA denials. A 2024 Senate committee report cited individual AI tools producing denial rates 16 times higher than human reviewers. Prior authorization AI spending jumped from $10 million in 2024 to $100 million in 2025 — a tenfold increase in a single year — with most of that capital targeting denial efficiency, not approval accuracy.
For prescription drugs specifically, none of this existed in a federal transparency framework. Until now.
Four Findings Pharmacy Operations Must Absorb
Electronic PA standards for pharmacy benefits launch October 1, 2027. CMS proposes requiring state Medicaid and CHIP FFS programs, Medicaid managed care plans, CHIP managed care entities, and QHP issuers on federally facilitated exchanges to support three NCPDP standards — SCRIPT, Formulary & Benefit (F&B), and Real-Time Prescription Benefit (RTPB) — beginning October 1, 2027. These standards enable providers to query formulary information in real time, determine drug coverage status, and exchange electronic PA requests and decisions. Most pharmacy workflows today handle this through fax queues, payer portal logins, and phone trees.
Decision windows tighten dramatically. Standard drug PA decisions must be issued within 24 hours. Expedited requests within 72 hours. Today, 18% of prescribers wait a week or more for PA approval, and 25% face waits exceeding two weeks. The 24-hour standard for standard drug requests is more aggressive than the 7-day window applied to non-drug items under CMS-0057-F. Payers will challenge this in comments.
AI-assisted denials now require specific clinical reasons. CMS-0062-P requires payers to provide a specific clinical reason for every AI-assisted drug PA denial. Generic denial language — “not medically necessary” without documented clinical basis — will not satisfy this standard when an algorithm drives the determination. Payers must also publish aggregate approval and denial data publicly, creating pharmaceutical authorization accountability that currently exists nowhere in federal law.
FHIR standards proposed for medical benefit drug PA. Under HIPAA’s Administrative Simplification provisions, HHS proposes adopting HL7 FHIR Da Vinci implementation guides for all covered entities exchanging electronic PA requests for drugs covered under the medical benefit. The rule creates a dual-track architecture: NCPDP standards govern pharmacy benefit drugs; FHIR governs medical benefit drugs. Specialty drugs that can route through either benefit require explicit determination logic upstream of authorization — logic most health system pharmacy programs haven’t built.
“The drug prior authorization process has operated as a policy-laundering mechanism for years. CMS-0062-P is the minimum viable accountability standard — and most pharmacy programs aren’t built for what it requires by 2027.”
Operational Impact: Four Concrete Obligations
Most pharmacy management systems aren’t built for what this rule requires. They handle prescription routing and dispensing. Prior authorization has lived in a separate operational silo — payer portals, fax queues, or third-party clearinghouses. CMS-0062-P proposes collapsing that silo into a structured, real-time API-driven workflow. That requires integration work, vendor readiness, and workflow redesign — none of which can be staffed in the final quarter before an October deadline.
Audit your current drug PA workflow end-to-end. Map every touchpoint: where authorization requests originate, how payer status is tracked, and where denials are documented. If any step involves a payer portal login or a fax queue, it is not NCPDP-ready under the proposed 2027 standard.
Ask your pharmacy management system vendor a direct question. What is your NCPDP SCRIPT, F&B, and RTPB compliance roadmap, and when does it ship? This question needs a written answer — not a roadmap slide. Vendors without a committed 2026–2027 development timeline create contract exposure before the deadline even arrives.
Document how AI currently influences your PA and DUR workflows. If your telepharmacy program uses clinical decision support tools that flag prior authorization requirements or recommend denial, your documentation must trace the basis for those recommendations explicitly. The AI transparency mandate applies to payers — but audit exposure flows downstream to operators when your workflows interface with payer AI systems.
Submit comments before June 15, 2026. Telepharmacy operators have the most operationally specific data on drug PA failure modes in remote clinical settings. That perspective is underrepresented in federal dockets. Comments grounded in real workflow data — average PA resolution time, abandonment rates, formulary exception frequency — carry weight. Generic support letters do not.
TheraIntel Perspective: The Compound Regulatory Context
CMS-0062-P is the right rule. Drug prior authorization has functioned as a policy-laundering mechanism for years. Payers deploy AI to accelerate denials, categorize the output as a “clinical determination,” then provide no mechanism for the treating clinician to understand the algorithm’s data inputs or logic.
Requiring a specific reason for every AI-assisted denial is the minimum viable accountability standard. It doesn’t fix the underlying financial incentive — payers are still rewarded for denials — but it creates a documented record that regulators, attorneys, and patients can act on. That’s a material shift.
The dual-track FHIR/NCPDP architecture is where this rule gets operationally dangerous. Specialty drugs that can route through either benefit — biologics, high-cost oral oncology agents, GLP-1 receptor agonists — require pharmacy programs to have benefit determination logic before authorization. Health systems without this routing layer will face workflow failures at exactly the drugs where authorization delays cause the most patient harm.
Combined with the CMS CRUSH anti-fraud initiative launched February 25, 2026 — which explicitly named telehealth and pharmacy billing practices as priority enforcement targets — telepharmacy programs now operate in the tightest regulatory environment of the past decade. A drug PA workflow that isn’t AI-auditable and NCPDP-documented isn’t just a compliance gap. It’s a liability that federal regulators now have clear statutory authority to pursue.
Three Actions Before June 15, 2026
Audit your drug PA workflow for NCPDP compliance readiness. Map every authorization touchpoint from prescription generation to payer decision. If your workflow includes a fax queue or manual payer portal step, document it now — those are your 2027 infrastructure gaps, and closing them takes longer than most organizations budget for.
Require written vendor commitment on SCRIPT, F&B, and RTPB timelines. Not a roadmap slide. A written delivery commitment with a date. Vendors who cannot provide this in writing by the end of Q2 should be flagged in your next contract review cycle. The October 2027 deadline will arrive before most organizations expect it.
Submit comments to CMS-0062-P with operational data. The comment docket is open through June 15. Telepharmacy operators have uniquely granular data on remote PA burden — denial rates, resolution timelines, abandonment rates in underserved markets. That data belongs in the federal record. It shapes the final rule. It is almost entirely absent from the docket right now.
The comment docket is CMS-0062-P. The deadline is June 15, 2026. The door is open now.